SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2681)4/9/2019 4:03:02 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3557
 
From the ALNY pre-clinical presentation on CNS/Ocular new siRNA constructs (https://www.alnylam.com/wp-content/uploads/2019/04/Milstein-CSHL-Oligosv6.pdf), only ocular-TTR was mentioned.

Nothing about wet/dry-AMD. Sound like CNS was primary focus (in addition to more on liver as target) of this extended alliance, so more and more I have feeling that they overpay/rushed into collaboration. Which is not TYPICAL for Schleifer! is he getting OLD, not anough *testosterones*???



To: Miljenko Zuanic who wrote (2681)5/17/2019 4:05:22 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3557
 
<I continue to be cautious optimistic with ADVM AAV program.>

At this point (1/3 reduction in iv gene-dose after lifting partial clinical hold), I am not sure what to do with my small ADVM holding!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News